Therefore, clinical translation of our finding that a highly selective A3AR agonist can prevent and reverse chemotherapy-induced cognitive decline, sensorimotor deficits and peripheral neuropathy should be feasible. This evidence concerns the gene ADORA3 and Mental deterioration.